-
HPV Therapy INO-3106 Demonstrates Clinical Efficacy against Rare Respiratory Tract Tumors
americanpharmaceuticalreview
April 11, 2019
HPV Therapy INO-3106 Demonstrates Clinical Efficacy against Rare Respiratory Tract Tumors.
-
CytomX slumps as BMS bails on 3 partnered projects
fiercebiotech
February 28, 2019
Amid an R&D update from CytomX is the news that Bristol-Myers Squibb has abandoned three programs, putting pressure on the biotech’s share price....
-
Using water and gold, Australian researchers discover ‘universal cancer biomarker’
fiercebiotech
January 02, 2019
Australian researchers at the University of Queensland have discovered a unique DNA structure that appears to be shared by many cancers and could be used to .....
-
NICE publishes updated guidance with expanded recommendation for Oncotype DX
pharmatimes
December 21, 2018
The National Institute for Health and Care Excellence (NICE) has announced the release of a second set of guidelines recommending three tests as options to help NHS clinicians decide whether
-
When good macrophages go bad
worldpharmanews
December 03, 2018
Researchers at Children's Hospital Los Angeles reveal a mechanism by which some cancers trick healthy cells into protecting tumors.
-
Obesity both feeds tumors and helps immunotherapy kill cancer
worldpharmanews
November 15, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors. The paradoxical findings, published today in Nature Medicine, give c
-
World Tumor Markers Testing Market 2018: Reagents & Instrumentation - Supplier Shares & Strategies, Country Segment Forecasts, Emerging Opportunities
biospace
April 20, 2018
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.
-
Propranolol delays tumour growth and increases survival when combined with immunotherapy
europeanpharmaceuticalreview
January 10, 2018
A common, inexpensive drug that is used to prevent heart attacks and lower blood pressure may also help melanoma patients live longer…
-
Higher mutational burdens in tumours linked to greater immunotherapy success, study finds
pharmafile
December 22, 2017
New research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Cancer Institute for Cancer Immunotherapy has indicated that the mutational burden can provide a strong indicator as to whether a cancer will respond to checkpoint inhibito
-
FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic pro
roche
December 05, 2017
Roche Corporation announced today that the FDA has approved the FoundationOne CDx ™ Foundation's comprehensive companion diagnostic method for personalized oncology treatment1